Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke

NCT ID: NCT03728738

Last Updated: 2020-03-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

182 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-25

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Placing the head of bed (HOB) at 0-degrees has been shown in small studies to improve blood flow to the brain in patients with ischemic stroke caused by large artery occlusions, thereby reducing stroke symptom worsening. This simple yet potentially impactful intervention has yet to be tested in a large clinical trial in hyperacute large artery ischemic stroke patients, but may provide nurses with a powerful contribution to acute stroke care that is capable of preventing worsening of stroke symptoms and promoting stabilization. Because stroke is the leading cause of preventable long-term disability in adults, this study may show that simple methods such as 0-degree HOB positioning should be considered one of the very first actions taken in the emergent management of acute ischemic stroke patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Positioning of the patient during hyperacute ischemic stroke (AIS) treatment is an important, yet understudied aspect of nursing care that could impact the course of treatment and clinical outcome. Since 1968, clinical symptom worsening in AIS patients has been documented with the head of bed (HOB) elevated to 30 degrees or higher, while clinical improvement or symptom stability has been noted with zero degree HOB positioning. Mechanisms for zero degree HOB clinical improvement include favorable gravitational blood flow conditions and recruitment of collateral blood channels, while in the case of treatment with clot-busting medications, increased blood flow may allow more medication to reach occluded arteries facilitating clot breakdown. Despite this, there is currently divide within the clinical community about what position is best for patients, although it has been argued that zero degree head positioning should be among the first steps taken to improve blood flow to the brain and prevent stroke symptom worsening. The investigators have shown that elevated ICP is absent in early AIS, and that pneumonia is rare using these piloted methods. However, no large clinical trial has examined efficacy and safety of zero degree HOB positioning within hyperacute large vessel occlusion (LVO) ischemic stroke patients with potentially viable brain tissue, leaving the acute stroke community confused as to what constitutes best practice. ZODIAC is a prospective randomized open blinded endpoint (PROBE) clinical trial of head positioning to determine if zero degree HOB positioning during the early phase of hyperacute LVO ischemic stroke management prevents neurological symptom worsening. Mechanical thrombectomy (MT) eligible patients (n=182) will be randomized to one of two groups: 1) Zero degree HOB positioning; or, 2) thirty degree HOB positioning. The hypothesis is that optimal HOB position can be determined by early neurological symptom worsening during the intervention (Aim 1) prior to initiation of the thrombectomy procedure, and the investigators propose that real-time deterioration may be a surrogate measure for decreased downstream perfusion, potentially impacting viability of brain at risk for infarction. Aim 2 will confirm that use of zero degree HOB positioning for AIS is safe. Use of this nursing measure holds significant promise as an innovative adjunct method to improve AIS symptoms, and ultimately reduce disability.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
Prospective randomized open blinded endpoint (PROBE) clinical trial using clinical assessors blinded to the intervention to determine neurologic deterioration on the NIH Stroke Scale Score following positioning to either zero degree or thirty degree heights.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zero Degree HOB

Randomization to zero degree head of bed positioning until the time of initiation of thrombectomy

Group Type EXPERIMENTAL

Head of Bed Positioning

Intervention Type PROCEDURE

The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation

Thirty Degree HOB

Randomization to thirty degree head of bed positioning until the time of initiation of thrombectomy

Group Type ACTIVE_COMPARATOR

Head of Bed Positioning

Intervention Type PROCEDURE

The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Head of Bed Positioning

The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ischemic stroke symptoms consistent with large artery occlusion
* Baseline standard of care non-contrast head CT (or MRI) negative for hemorrhage or mass-effect
* Evidence of arterial occlusion on standard of care CT angiography or MR angiography
* Favorable neuroimaging (Alberta Stroke Program Early Computed Tomography Score \[ASPECTS\] \> 6 in anterior circulation stroke; not applicable in posterior circulation stroke)
* Ordered treatment with mechanical thrombectomy
* Pre-stroke baseline modified Rankin Score (mRS) \< 1
* Ability to enroll, randomize and begin the intervention within the Emergency Department

Exclusion Criteria

* Non-English speaking subjects will be excluded due to use of English language instruments (modified Rankin Scale \[mRS\] \& NIHSS) and English speaking investigators
* Pregnancy or suspicion of pregnancy
* Evidence or suspicion of vomiting any time prior to consent which could predispose to aspiration pneumonia and therefore confound determination of protocol safety
* Anticipated palliative care referral
* Evidence of evolving malignant infarction on admission noncontrast CT (or MRI)
* Need for intubation with mechanical ventilation, or non-invasive ventilatory support with either bi-level positive airway pressure (BiPAP) or continuous positive airway pressure (CPAP)
* Inability to tolerate zero-degree positioning due to congestive heart failure, preexisting pneumonia, chronic obstructive pulmonary disease, or other medical condition
* Admission chest radiograph positive for pleural effusion, pulmonary edema, pneumonia, or other pulmonary condition that may confound determination of protocol safety
* Abnormal breath sounds on admission assessment that may confound determination of protocol safety
* Lack of a telephone and/or permanent address predisposing patients to be lost to follow up
* Enrollment in another clinical trial that may affect our primary or secondary endpoints
* In the absence of a consenting legal next of kin, any medical, psychological, cognitive, social or legal condition that would interfere with informed consent and/or capacity to comply with all study requirements, including the necessary time commitment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Nursing Research (NINR)

NIH

Sponsor Role collaborator

University of Tennessee

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anne Alexandrov

Professor of Nursing & Professor of Neurology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anne W Alexandrov, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Tennessee Health Science Center at Memphis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mobile Infirmary Medical Center

Mobile, Alabama, United States

Site Status RECRUITING

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Site Status NOT_YET_RECRUITING

Doctors Medical Center

Modesto, California, United States

Site Status RECRUITING

Northwestern Central DuPage Hospital

Winfield, Illinois, United States

Site Status RECRUITING

University of Louisville Hospital

Louisville, Kentucky, United States

Site Status RECRUITING

Moses Cone Medical Center

Greensboro, North Carolina, United States

Site Status NOT_YET_RECRUITING

Saint Francis Health System

Tulsa, Oklahoma, United States

Site Status RECRUITING

Hershey Medical Center - Penn State Health

Hershey, Pennsylvania, United States

Site Status RECRUITING

Methodist University Hospital

Memphis, Tennessee, United States

Site Status RECRUITING

Medical City - Fort Worth

Fort Worth, Texas, United States

Site Status RECRUITING

Memorial Hermann Hospital

Houston, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stephanie Breuer, MS

Role: CONTACT

901-448-6424

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jackie Owens, MSN

Role: primary

David Liebeskind, MD

Role: primary

Dharati Trivedi, MS

Role: primary

Abbigayle Doerr, DNP

Role: primary

Betsy Wise, MSN

Role: primary

Sharon Biby, MSN

Role: primary

Matthew Holzmann, MSN

Role: primary

Alicia Richardson, MSN

Role: primary

Anne W Alexandrov, PhD

Role: primary

Cara Guthrie-Chu, MSN

Role: primary

Nicole Gonzales, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Alexandrov AW, Shearin AJ, Mandava P, Torrealba-Acosta G, Elangovan C, Krishnaiah B, Nearing K, Robinson E, Guthrie-Chu C, Holzmann M, Fill B, Trivedi DR, Richardson A, Middleton S, Brewer BB, Liebeskind DS, Goyal N, Grotta JC, Alexandrov AV; ZODIAC Investigators. Optimal Head-of-Bed Positioning Before Thrombectomy in Large Vessel Occlusion Stroke: A Randomized Clinical Trial. JAMA Neurol. 2025 Sep 1;82(9):905-914. doi: 10.1001/jamaneurol.2025.2253.

Reference Type DERIVED
PMID: 40465238 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01NR017850-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R01NR017850-01

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Augmenting Cerebral Blood Flow in Acute Ischemic Stroke
NCT06911385 NOT_YET_RECRUITING PHASE1/PHASE2